Developing Gene-Based Therapeutics

Matrix Biomed, Inc. is a biopharmaceutical company focused on delivering gene-based therapeutics. Gene-based therapeutics are directed to address both the dysregulation of multiple genes as well as their interactions in gene regulatory networks. Matrix Biomed, Inc. creates extensive gene regulatory networks and gene co-expression networks that are able to identify correlations between genes indicating which genes are active or inactive simultaneously. By redefining human diseases within these networks, Matrix Biomed, Inc. gains a broader understanding of the disease mechanism and drug-disease mechanism allowing Matrix Biomed, Inc. to accelerate the discovery and identification of novel therapeutic approaches to revert a disease state to a healthy state.

Matrix Biomed, Inc. departs with standard industry practices by extensively exploring the functional connection between drugs, genes, and diseases. By departing with these practices, Matrix Biomed, Inc.’s objective is to increase the relatively low rate at which novel drug candidates are translated into effective clinical therapies. With an average development timeframe of 15 years, a cost of over 1 billion U.S., and a success rate of less than ten percent for discovery of a single novel drug, the pharmaceutical industry is in dire need of reformed models and practices. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state.

Currently, Matrix Biomed, Inc. gene-based therapeutics are directed to therapies and drug products to make cancer treatment more manageable and successful through the elimination of the dose-limiting, life-threatening, and treatment-inhibiting toxicities associated with chemotherapy and radiotherapy. Radiation and chemotherapy-induced toxicity remains one of the most significant barriers to the delivery of curative doses of cancer chemotherapy. Particularly troubling are the toxicities specific to individual chemotherapeutic agents that, at minimum, limit the curative dose of cancer chemotherapy and, at a maximum, are lethal to the patient. Some of the most common chemotherapeutic agents belong to one of three classes: anthracyclines (doxorubicin), platinum-based agents (cisplatin), and taxanes (taxol/paclitaxel). Matrix Biomed, Inc.’s current clinical trial designs focus on the prevention of toxicities associated with doxorubicin, cisplatin, and paclitaxel administration.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt